Relay Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Relay Therapeutics, Inc. (RLAY) reported Increase (Decrease) in Deferred Revenue of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-06
- Relay Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was $0.00.
- Relay Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was $0.00.
- Relay Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-06-30 was $0.00.
- Relay Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-03-31 was -$7.68M.
- Relay Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2025 was -$7.68M, a 200.00% decline from fiscal 2024.
- Relay Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2024 was $7.68M.
- Relay Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2022 was -$248.00K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | -$7.68M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | -$7.68M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$7.68M 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | -$7.68M 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | $7.68M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $24.00K 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $15.00K 10-Q · filed 2024-08-06 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$83.00K derived: sum of 2 quarters · filed 2025-02-26 | -$166.00K derived: sum of 3 quarters · filed 2025-02-26 | -$248.00K 10-K · filed 2025-02-26 |
| 2022-09-30 | -$83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$166.00K derived: sum of 2 quarters · filed 2023-11-02 | -$248.00K 10-Q · filed 2023-11-02 | |
| 2022-06-30 | -$83.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$165.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$82.00K 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |